子宫颈癌防治展望

被引:33
作者
章文华
机构
[1] 中国医学科学院北京协和医学院肿瘤医院妇瘤科
关键词
D O I
暂无
中图分类号
R737.33 [子宫肿瘤];
学科分类号
100112 [医学生物化学与分子生物学];
摘要
<正>乔友林教授,博士研究生与博士后导师,中国医学科学院北京协和医学院肿瘤研究所流行病学研究室主任,中国癌症基金会副秘书长与国际合作部主任。先后就读或工作于华西医科大学公共卫生学院、大连医科大学、美国约翰斯·霍普金斯大学公共卫生学院,美国国家卫生研究院/国立癌症研究所(NIH/NCI)癌预防控制部。现兼任中国抗癌协会肿瘤流行病专业委员会副主任委员、卫生部疾病预防控制局癌症早诊早治专家委员会副主任委员与子宫颈癌专家组组长。世界卫生组织(WHO)总干事癌症防治专家组成员、WHO HPV疫苗专家顾问委员会成员、WHO HPV全球人群监测专家顾问委员会成员、国际抗癌联盟(UICC)全球癌症控制智囊团成员。
引用
收藏
页码:105 / 108
页数:4
相关论文
共 10 条
[1]
复发性子宫颈癌调强放射治疗的临床观察 [J].
黄曼妮 ;
章众 ;
安菊生 ;
高菊珍 ;
戴建荣 ;
吴令英 .
癌症进展, 2008, (05) :449-453
[2]
子宫颈癌筛查方法的横断面比较研究 [J].
乔友林 ;
章文华 ;
李凌 ;
潘秦镜 ;
杨玲 ;
吴令英 ;
戍寿德 ;
李爱玲 ;
张询 ;
任生达 ;
Belinson J .
中国医学科学院学报, 2002, (01) :50-53
[4]
关于子宫颈上皮内瘤变诊治问题的讨论.[J]..中华肿瘤杂志.2009, 04
[5]
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women [J].
Paovonen, J. ;
Naud, P. ;
Salmeron, J. ;
Wheeler, C. M. ;
Chow, S-N ;
Apter, D. ;
Kitchener, H. ;
Castellsague, X. ;
Teixeira, J. C. ;
Skinner, S. R. ;
Hedrick, J. ;
Jaisamrarn, U. ;
Limson, G. ;
Garland, S. ;
Szarewski, A. ;
Romanowski, B. ;
Aoki, F. Y. ;
Schwarz, T. F. ;
Poppe, W. A. J. ;
Bosch, F. X. ;
Jenkins, D. ;
Hardt, K. ;
Zahaf, T. ;
Descamps, D. ;
Struyf, F. ;
Lehtinen, M. ;
Dubin, G. .
LANCET, 2009, 374 (9686) :301-314
[6]
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years.[J].Romanowski B;de Borba P Colares;Naud P S;Roteli-Martins C M;De Carvalho N S;Teixeira J C;Aoki F;Ramjattan B;Shier R M;Somani R;Barbier S;Blatter M M;Chambers C;Ferris D;Gall S A;Guerra F A;Harper D M;Hedrick J A;Henry D C;Korn A P;Kroll R;Moscicki A-B;Rosenfeld W D;Sullivan B J;Thoming C S;Tyring S K;Wheeler C M;Dubin G;Schui
[7]
A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China [J].
Qiao, You-lin ;
Sellors, John W. ;
Eder, Paul S. ;
Bao, Yan-ping ;
Lim, Jeanette M. ;
Zhao, Fang-hui ;
Weigl, Bernhard ;
Zhang, Wen-hua ;
Peck, Roger B. ;
Li, Ling ;
Chen, Feng ;
Pan, Qing-jing ;
Lorincz, Attila T. .
LANCET ONCOLOGY, 2008, 9 (10) :929-936
[8]
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial [J].
Paavonen, Jorma ;
Jenkins, David ;
Bosch, F. Xavier ;
Naud, Paulo ;
Salmeron, Jorge ;
Wheeler, Cosette M. ;
Chow, Song-Nan ;
Apter, Dan L. ;
Kitchener, Henry C. ;
Castellsague, Xavier ;
de Carvalho, Newton S. ;
Skinner, S. Rachel ;
Harper, Diane M. ;
Hedrick, James A. ;
Jaisamrarn, Unnop ;
Limson, Genara A. M. ;
Dionne, Marc ;
Quint, Wim ;
Spiessens, Bart ;
Peeters, Pascal ;
Struyf, Frank ;
Wieting, Susan L. ;
Lehtinen, Matti O. ;
Dubin, Gary .
LANCET, 2007, 369 (9580) :2161-2170
[9]
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.[J].Diane M Harper;Eduardo L Franco;Cosette M Wheeler;Anna-Barbara Moscicki;Barbara Romanowski;Cecilia M Roteli-Martins;David Jenkins;Anne Schuind;Sue Ann Costa Clemens;Gary Dubin.The Lancet.2006, 9518
[10]
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial [J].
Villa, LL ;
Costa, RLR ;
Petta, CA ;
Andrade, RP ;
Ault, KA ;
Giuliano, AR ;
Wheeler, CM ;
Koutsky, LA ;
Malm, C ;
Lehtinen, M ;
Skjeldestad, FE ;
Olsson, SE ;
Steinwall, M ;
Brown, DR ;
Kurman, R ;
Ronnett, BM ;
Stoler, MH ;
Ferenczy, A ;
Harper, DM ;
Tamms, GM ;
Yu, J ;
Lupinacci, L ;
Railkar, R ;
Taddeo, FJ ;
Jansen, KU ;
Esser, MT ;
Sings, HL ;
Saah, AJ ;
Lupinacci, L .
LANCET ONCOLOGY, 2005, 6 (05) :271-278